SERMs for persistent pubertal gynecomastia
Both were associated with improvement; raloxifene response appeared higher.
Not randomized; pubertal population.
Original source ↗Loading TrenasCycles…
TrenasCycles
Loading TrenasCycles…
Ancillary / SERM
Evista
Raloxifene is discussed for gyno because it blocks estrogen's action in breast tissue. It works differently from estrogen-lowering drugs such as anastrozole, and results for male breast enlargement are less well studied. Hot flashes and leg cramps can occur, with blood clots and stroke risk in susceptible people the bigger concerns.
EVISTA osteoporosis and breast-cancer-risk indications in postmenopausal women. This label amount is not an established male gynecomastia or bodybuilding regimen.
Small observational pediatric/male gynecomastia data suggest possible benefit, but evidence is weaker than large approved-indication trials.
Venous thromboembolism, stroke risk in susceptible patients, hot flashes and leg cramps.
Health problem link: selected gynecomastia cases after diagnostic evaluation; not general estrogen control.
Approved for osteoporosis and breast-cancer-risk reduction in postmenopausal women; male gynecomastia use is off-label.
Both were associated with improvement; raloxifene response appeared higher.
Not randomized; pubertal population.
Original source ↗Compared endocrine effects of tamoxifen and raloxifene.
Very small, short study; not gynecomastia efficacy.
Original source ↗